187 related articles for article (PubMed ID: 27706681)
1. Reversal of cisplatin resistance in non-small cell lung cancer stem cells by Taxus chinensis var.
Jiang YQ; Xu XP; Guo QM; Xu XC; Liu QY; An SH; Xu JL; Su F; Tai JB
Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706681
[TBL] [Abstract][Full Text] [Related]
2. A milbemycin compound isolated from Streptomyces Sp. FJS31-2 with cytotoxicity and reversal of cisplatin resistance activity in A549/DDP cells.
Li XQ; Yue CW; Xu WH; Lü YH; Huang YJ; Tian P; Liu T
Biomed Pharmacother; 2020 Aug; 128():110322. PubMed ID: 32505822
[TBL] [Abstract][Full Text] [Related]
3. Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU.
Shi LX; Ma R; Lu R; Xu Q; Zhu ZF; Wang L; Zhou CL; Li XL; Zhang HL; Yao Z
Cancer Lett; 2008 Sep; 269(1):101-10. PubMed ID: 18538471
[TBL] [Abstract][Full Text] [Related]
4. ABCB1, ABCC1, and LRP gene expressions are altered by LDL, HDL, and serum deprivation in a human doxorubicin-resistant uterine sarcoma cell line.
Celestino AT; Levy D; Maria Ruiz JL; Bydlowski SP
Biochem Biophys Res Commun; 2015 Feb; 457(4):664-8. PubMed ID: 25603048
[TBL] [Abstract][Full Text] [Related]
5. Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs.
Pesic M; Markovic JZ; Jankovic D; Kanazir S; Markovic ID; Rakic L; Ruzdijic S
J Chemother; 2006 Feb; 18(1):66-73. PubMed ID: 16572896
[TBL] [Abstract][Full Text] [Related]
6. Expression of P-gp, MRP, LRP, GST-π and TopoIIα and intrinsic resistance in human lung cancer cell lines.
Wang J; Zhang J; Zhang L; Zhao L; Fan S; Yang Z; Gao F; Kong Y; Xiao GG; Wang Q
Oncol Rep; 2011 Nov; 26(5):1081-9. PubMed ID: 21805041
[TBL] [Abstract][Full Text] [Related]
7. Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells.
Ikuta K; Takemura K; Sasaki K; Kihara M; Nishimura M; Ueda N; Naito S; Lee E; Shimizu E; Yamauchi A
Biol Pharm Bull; 2005 Apr; 28(4):707-12. PubMed ID: 15802814
[TBL] [Abstract][Full Text] [Related]
8. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
9. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
[TBL] [Abstract][Full Text] [Related]
10. TFPI-2 downregulates multidrug resistance protein in 5-FU-resistant human hepatocellular carcinoma BEL-7402/5-FU cells.
Lu F; Hou YQ; Song Y; Yuan ZJ
Anat Rec (Hoboken); 2013 Jan; 296(1):56-63. PubMed ID: 23125179
[TBL] [Abstract][Full Text] [Related]
11. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
12. The expression and significance of MRP1, LRP, TOPOIIβ, and BCL2 in tongue squamous cell carcinoma.
Zhang B; Liu M; Tang HK; Ma HB; Wang C; Chen X; Huang HZ
J Oral Pathol Med; 2012 Feb; 41(2):141-8. PubMed ID: 21793937
[TBL] [Abstract][Full Text] [Related]
13. Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma.
Hao C; Liu G; Tian G
Ther Adv Respir Dis; 2019; 13():1753466619866097. PubMed ID: 31368411
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.
Chen YL; Yang TY; Chen KC; Wu CL; Hsu SL; Hsueh CM
Cell Oncol (Dordr); 2016 Oct; 39(5):411-433. PubMed ID: 27306525
[TBL] [Abstract][Full Text] [Related]
16. Stephania Tetrandra and Ginseng-Containing Chinese Herbal Formulation NSENL Reverses Cisplatin Resistance in Lung Cancer Xenografts.
Jin L; Xu M; Luo XH; Zhu XF
Am J Chin Med; 2017; 45(2):385-401. PubMed ID: 28231742
[TBL] [Abstract][Full Text] [Related]
17. Construction and application of a lung cancer stem cell model: antitumor drug screening and molecular mechanism of the inhibitory effects of sanguinarine.
Yang J; Fang Z; Wu J; Yin X; Fang Y; Zhao F; Zhu S; Li Y
Tumour Biol; 2016 Oct; 37(10):13871-13883. PubMed ID: 27485114
[TBL] [Abstract][Full Text] [Related]
18. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications.
Berger W; Setinek U; Hollaus P; Zidek T; Steiner E; Elbling L; Cantonati H; Attems J; Gsur A; Micksche M
J Cancer Res Clin Oncol; 2005 Jun; 131(6):355-63. PubMed ID: 15856298
[TBL] [Abstract][Full Text] [Related]
19. Wilms' tumor 1 enhances Cisplatin-resistance of advanced NSCLC.
Wu C; Wang Y; Xia Y; He S; Wang Z; Chen Y; Wu C; Shu Y; Jiang J
FEBS Lett; 2014 Dec; 588(24):4566-72. PubMed ID: 25447528
[TBL] [Abstract][Full Text] [Related]
20. shRNA-mediated silencing of sorcin increases drug chemosensitivity in myeloma KM3/DDP and U266/ADM cell lines.
Xu P; Jiang YF; Wang JH
Int J Clin Exp Pathol; 2015; 8(3):2300-10. PubMed ID: 26045737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
